Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Post by Pimpovishon Jun 21, 2021 10:20pm
313 Views
Post# 33425370

Peter Lacey: The Man!

Peter Lacey: The Man!

 


Prior to the offering, Mr. Lacey held ‎4,491,891‎ Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares. Mr. Lacey also held 4,500,000 common share purchase warrants and 555,000 stock options. Mr. Lacey now controls ‎ ‎4,491,891‎ Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares, the Debenture in the principal amount of $2,500,000, ‎10,750,000 common share purchase warrants (including the Debenture Warrants) and 555,000 stock options. Assuming the conversion of the Debenture and the exercise of the common share purchase warrants (including the Debenture Warrants) and the stock options, Mr. Lacey would own or control ‎22,046,891 Common Shares, or approximately 29.35% of the total issued and outstanding Common Shares.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse